SecBot SecBot
144 ·Filed Sep 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001462808-26-000008
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale tied to RSU vesting, not a discretionary insider sell signal. No bearish read-through. Monitor for any unplanned open-market sales by insiders, but this filing alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$195.92
T+0 close · Sep 15, 2026 · via day close
Latest settled
−3.82%
T+20 · $188.44 · next T+60 in 23d
Vs SPY
−7.00%
α at T+20
Latest observation
−4.92%
T+41 · FF3 residual α
  1. T+0 · Sep 16 $195.92entry
  2. T+1 · 2mo ago +0.52%α −0.61% · $196.94
  3. T+5 · 8w ago −2.64%α −5.21% · $190.74
  4. T+20 · 5w ago −3.82%α −7.00% · $188.44
  5. T+43 · todayOpen
  6. T+60 · in 23d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Stephen Michael Kelsey, an officer of Revolution Medicines, Inc., filed a Form 144 indicating intent to sell 5,415 shares of common stock, with an estimated aggregate market value of approximately $1,103,414.55. The shares were acquired via RSU vesting on September 15, 2026, and the sale is intended to cover tax withholding obligations related to the vesting. This is a routine, small-scale sale relative to the officer's total holdings and the company's $44B market cap, with no bearish signal.

Key Facts

  • Officer Stephen Michael Kelsey filed Form 144 to sell 5,415 shares of RVMD common stock.
  • Estimated aggregate market value of the proposed sale is ~$1.1M.
  • Shares were acquired via RSU vesting on September 15, 2026, and the sale is for tax withholding purposes.
  • Kelsey still holds 92,531 shares of common stock as of September 11, 2026, valued at ~$18.7M.
  • The sale represents a small fraction of his total holdings and is not a discretionary open-market sale.

Financial Impact

~$1.1M proposed sale, representing ~0.003% of RVMD's $44B market cap

dilutioninsider holdings

Risk Factors

  • No material risk identified from this filing; the sale is non-discretionary and small in scale.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001462808-26-000008
Document: 0001462808-26-000008-index.html0001462808-26-000008
Document: 0001462808-26-000008.txt0001462808-26-000008

US Market Status

Market Closed · Opens in 8h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026